Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alberto Del Rio-Espinola

Showing results (1-10 of 15) with videos related to

Pageof 2
Sort By:
Toxicologic Pathology|December 10, 2016
Translational Safety GeneticsPriyasma Bhoumik, Alberto Del Rio-Espinola, Florian Hahne, et al.
Expert Review of Molecular Diagnostics|July 5, 2008
Genetics of stroke: a review of recent advancesSophie Domingues-Montanari, Maite Mendioroz, Alberto del Rio-Espinola, et al.
Toxicological Sciences : an Official Journal of the Society of Toxicology|October 23, 2021
An Afucosylated Anti-CD32b Monoclonal Antibody Induced Platelet-Mediated Adverse Events in a Human Fcγ Receptor Transgenic Mouse Model and Its Potential Human TranslatabilityBabette Wolf, Valentina Jeliazkova-Mecheva, Alberto Del Rio-Espinola, et al.
Toxicological Sciences : an Official Journal of the Society of Toxicology|December 14, 2021
Erratum to: An Afucosylated Anti-CD32b Monoclonal Antibody Induced Platelet-Mediated Adverse Events in a Human Fcγ Receptor Transgenic Mouse Model and Its Potential Human TranslatabilityBabette Wolf, Valentina Jeliazkova-Mecheva, Alberto Del Rio-Espinola, et al.
Nature Reviews. Drug Discovery|October 19, 2022
Using human genetics to improve safety assessment of therapeuticsKeren J Carss, Aimee M Deaton, Alberto Del Rio-Espinola, et al.
Molecular Therapy. Methods & Clinical Development|October 27, 2021
Evaluation of two <i>in vitro</i> assays for tumorigenicity assessment of CRISPR-Cas9 genome-edited cellsMyriam Lemmens, Benoit Fischer, Michael Zogg, et al.
Cytotherapy|May 20, 2025
Evaluating teratoma formation risk of pluripotent stem cell-derived cell therapy products: a consensus recommendation from the Health and Environmental Sciences Institute's International Cell Therapy CommitteeTakeshi Watanabe, Shin La Shu, Alberto Del Rio-Espinola, et al.
JCI Insight|March 15, 2017
Retinoic-acid-orphan-receptor-C inhibition suppresses Th17 cells and induces thymic aberrationsChristine Guntermann, Alessandro Piaia, Marie-Laure Hamel, et al.
Pharmacogenomics|April 6, 2013
Genes involved in hemorrhagic transformations that follow recombinant t-PA treatment in stroke patientsIsrael Fernandez-Cadenas, Alberto Del Rio-Espinola, Sophie Domingues-Montanari, et al.
Cerebrovascular Diseases (Basel, Switzerland)|April 2, 2010
Association of a genetic variant in the ALOX5AP with higher risk of ischemic stroke: a case-control, meta-analysis and functional studySophie Domingues-Montanari, Israel Fernández-Cadenas, Alberto del Rio-Espinola, et al.
Pageof 2

Showing results (1-10 of 15) with videos related to

Sort By:
Pageof 2
Toxicologic Pathology|December 10, 2016
Translational Safety GeneticsPriyasma Bhoumik, Alberto Del Rio-Espinola, Florian Hahne, et al.
Expert Review of Molecular Diagnostics|July 5, 2008
Genetics of stroke: a review of recent advancesSophie Domingues-Montanari, Maite Mendioroz, Alberto del Rio-Espinola, et al.
Toxicological Sciences : an Official Journal of the Society of Toxicology|October 23, 2021
An Afucosylated Anti-CD32b Monoclonal Antibody Induced Platelet-Mediated Adverse Events in a Human Fcγ Receptor Transgenic Mouse Model and Its Potential Human TranslatabilityBabette Wolf, Valentina Jeliazkova-Mecheva, Alberto Del Rio-Espinola, et al.
Toxicological Sciences : an Official Journal of the Society of Toxicology|December 14, 2021
Erratum to: An Afucosylated Anti-CD32b Monoclonal Antibody Induced Platelet-Mediated Adverse Events in a Human Fcγ Receptor Transgenic Mouse Model and Its Potential Human TranslatabilityBabette Wolf, Valentina Jeliazkova-Mecheva, Alberto Del Rio-Espinola, et al.
Nature Reviews. Drug Discovery|October 19, 2022
Using human genetics to improve safety assessment of therapeuticsKeren J Carss, Aimee M Deaton, Alberto Del Rio-Espinola, et al.
Molecular Therapy. Methods & Clinical Development|October 27, 2021
Evaluation of two <i>in vitro</i> assays for tumorigenicity assessment of CRISPR-Cas9 genome-edited cellsMyriam Lemmens, Benoit Fischer, Michael Zogg, et al.
Cytotherapy|May 20, 2025
Evaluating teratoma formation risk of pluripotent stem cell-derived cell therapy products: a consensus recommendation from the Health and Environmental Sciences Institute's International Cell Therapy CommitteeTakeshi Watanabe, Shin La Shu, Alberto Del Rio-Espinola, et al.
JCI Insight|March 15, 2017
Retinoic-acid-orphan-receptor-C inhibition suppresses Th17 cells and induces thymic aberrationsChristine Guntermann, Alessandro Piaia, Marie-Laure Hamel, et al.
Pharmacogenomics|April 6, 2013
Genes involved in hemorrhagic transformations that follow recombinant t-PA treatment in stroke patientsIsrael Fernandez-Cadenas, Alberto Del Rio-Espinola, Sophie Domingues-Montanari, et al.
Cerebrovascular Diseases (Basel, Switzerland)|April 2, 2010
Association of a genetic variant in the ALOX5AP with higher risk of ischemic stroke: a case-control, meta-analysis and functional studySophie Domingues-Montanari, Israel Fernández-Cadenas, Alberto del Rio-Espinola, et al.
Pageof 2